Pretreatment age and serum lactate dehydrogenase as predictors of synchronous second primary cancer in patients with nasopharyngeal carcinoma

Yeh, Ching-Fa; Ho, Ching‐Yin; Chin, Yu‐Ching; Shu, Ching‐Fong; Chao, Yun‐Ting; Lan, Ming‐Ying

doi:10.1016/j.oraloncology.2020.104990

Cited by 6 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with EBV DNA ≥2000 copies/ml did have poor survival rates in stage II nasopharyngeal carcinoma. Aside from total tumor volume and EBV DNA, elevated LDH was also related to higher tumor burden and more tumor angiogenesis, and predicted poor survival in various tumor, including nasopharyngeal carcinoma 21 . In this study, LDH was further proved to be an independent prognostic factor.…”

Section: Discussionmentioning

confidence: 53%

Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era

et al. 2021

View full text Add to dashboard Cite

Purpose We aimed to develop and prospectively validate a risk score model to guide individualized concurrent chemoradiotherapy (CCRT) for patients with stage II nasopharyngeal carcinoma (NPC) in intensity‐modulated radiotherapy (IMRT) era. Materials and Methods In total, 1220 patients who received CCRT or IMRT alone were enrolled in this study, including a training cohort (n = 719), a validation cohort (n = 307), and a prospective test cohort (n = 194). Patients were stratified into different risk groups by a risk score model based on independent prognostic factors, which were developed in the training cohort. Survival rates were compared by the log‐rank test. The validation and prospective test cohorts were used for validation. Results Total tumor volume, Epstein–Barr virus DNA, and lactate dehydrogenase were independent risk factors for failure‐free survival (FFS, all p < 0.05). A risk score model based on these three risk factors was developed to classify patients into low‐risk group (no risk factor, n = 337) and high‐risk group (one or more factors, n = 382) in the training cohort. In the high‐risk group, CCRT had better survival rates than IMRT alone (5‐year FFS: 82.6% vs. 74.0%, p = 0.028). However, there was no survival difference between CCRT and IMRT alone either in the whole training cohort (p = 0.15) or in the low‐risk group (p = 0.15). The results were verified in the validation and prospective test cohorts. Conclusion A risk score model was developed and prospectively validated to precisely select high‐risk stage II NPC patients who can benefit from CCRT, and thus guided individualized treatment in IMRT era.

show abstract

Section: Discussionmentioning

confidence: 53%

Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Elevated LDH levels are a negative prognostic factor for lymphoma and several solid cancers, including renal cell carcinoma, nasopharyngeal carcinoma, sarcoma, and lung cancer (31). Glycolysis is the main energy source for malignant cells.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features and Prognostic Factors of Sinonasal Rhabdomyosarcoma

Huang

Yeh

2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: Sinonasal rhabdomyosarcoma (RMS) is a rare soft tissue malignancy. Due to the limited cases, the clinicopathological features and prognostic factors are still not well understood. Patients and Methods: This retrospective review included eight patients with sinonasal RMS at our institution between 2004 and 2020. Patient demographics, tumor features, Intergroup Rhabdomyosarcoma Study Group (IRSG) stage and clinical group, treatment strategy, and survival rates were evaluated. Kaplan-Meier analysis and log-rank tests were performed to analyze the possible prognostic factors. Results: We observed a predominance of male sex and alveolar-type tumor in sinonasal RMS. Nasal obstructions and neck masses were the most common symptoms. Patients with pretreatment lactate dehydrogenase (LDH) levels >400 U/l and negative immunohistochemical staining for desmin or MyoD1 had lower survival rates. Conclusion: In patients with sinonasal RMS, pretreatment LDH levels >400 U/l and negative immunohistochemical staining for desmin or MyoD1 may suggest a poor prognosis. These factors can not only contribute to the prediction of prognosis in patients with sinonasal RMS but also facilitate the design of more appropriate treatment strategies.Rhabdomyosarcoma (RMS) is a malignant tumor with a propensity for skeletal muscle differentiation. It is the most common soft tissue sarcoma in children, accounting for approximately 50% of all pediatric soft tissue sarcomas (1-3). However, it is rare in adults, accounting for <1% of all adult malignancies. RMS can be classified into four histological subtypes: embryonal (ERMS), alveolar (ARMS), pleomorphic (PRMS), and spindle cell/sclerotic. ERMS is the most common type, followed by ARMS (4, 5). ARMS is more aggressive than the other subtypes and is often associated with a worse prognosis. ARMS can be further classified according to the presence or absence of the paired box (Pax) proteins 3 and 7/forkhead box O1 (PAX3/7-FOXO1) fusion gene. The outcome in patients with fusionnegative ARMS is indistinguishable from that in ERMS and differs significantly from that in ARMS with fusion genes (6).Approximately 35% of RMS cases arise in the head and neck region, including the orbital, parameningeal, and nonparameningeal areas (3). Tumors in the parameningeal areas have the worst outcome among those in the head and neck region, especially the paranasal sinuses, owing to the structural complexity and tendency for central nervous system (CNS) and skull base invasion (3,7,8). As the tumor location affects the disease prognosis, it appears alongside the usual TNM in the Intergroup Rhabdomyosarcoma Staging Group (IRSG) staging of RMS (9). In addition, the IRSG clinical group for RMS is based on the extent of residual disease after resection and evidence of regional lymph node (LN) or distal metastasis, which is one of the most important prognostic factors in RMS. The treatment strategy for RMS, which includes surgery, chemotherapy, and radiotherapy, is risk-based. The main treatment strategy for si...

show abstract

“…Since the data from large sample size research is lacking, the optimal cutoff value still needs further investigation. Thirdly, some other clinicopathological factors which may affect the prognosis of patients were not included, such as EBV-DNA [32], LDH [33]. It may bring bias to the results.…”

Section: Discussionmentioning

confidence: 99%

Combination of CD47 Expression and SIRI as a Prognostic Factor in Nasopharyngeal Carcinoma Patients

Deng

Feng

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

Aim: The present study aimed to investigate the prognostic value of the combination of CD47 expression and SIRI level in nasopharyngeal carcinoma (NPC) patients.Materials & Methods: NPC patients who received radical chemoradiation therapy between January 2012 and December 2016 at the Second Xiangya Hospital were retrospectively reviewed. The clinical and laboratory data was collected from the electro-history system. The expression of CD47 was detected by immunohistochemical (IHC) method. Receiver operating characteristic curve analysis was used to determine the optimal cut-off value. Survival curves were analyzed using Kaplan-Meier method, and Cox proportional hazard model was used to identify prognostic factors.Results: A cohort of 183 NPC patients were enrolled. CD47 was highly expressed in 36.1% (66/183) patients at a cut-off value of 35%. And SIRI was elevated in 35.0% (64/183) patients at a cut-off value of 0.94. CD47 expression had no significant correlation with NPC patients’ age, gender, ECOG status, clinical stage, smoking history or chemo-agent. While SIRI level was significantly higher in male patients and patients who has smoking history. Univariate analyzes shown that younger age, better ECOG PS, earlier clinical stage, and low expression of CD47 and SIRI level predicts better PFS, while better ECOG PS, earlier clinical stage, and low expression of CD47 and SIRI level predicts longer OS. Further multivariate Cos regression model showed that aside from ECOG PS and clinical stage, CD47 and SIRI statue was an independent prognostic factor for PFS and OS.Conclusion: Our findings indicate that the combination of CD47 expression and SIRI level might be a promising prognostic predictor for the NPC patients.

show abstract

Pretreatment age and serum lactate dehydrogenase as predictors of synchronous second primary cancer in patients with nasopharyngeal carcinoma

Cited by 6 publications

References 33 publications

Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era

Development and prospective validation of a risk score model in guiding individualized concurrent chemoradiotherapy in stage II nasopharyngeal carcinoma in intensity‐modulated radiotherapy era

Clinicopathological Features and Prognostic Factors of Sinonasal Rhabdomyosarcoma

Combination of CD47 Expression and SIRI as a Prognostic Factor in Nasopharyngeal Carcinoma Patients

Contact Info

Product

Resources

About